Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
24.91
+0.13 (0.52%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Elanco Animal Health Revenue
Elanco Animal Health had revenue of $1.37B in the quarter ending March 31, 2026, with 14.92% growth. This brings the company's revenue in the last twelve months to $4.89B, up 10.53% year-over-year. In the year 2025, Elanco Animal Health had annual revenue of $4.72B with 6.22% growth.
Revenue (ttm)
$4.89B
Revenue Growth
+10.53%
P/S Ratio
2.54
Revenue / Employee
$494,242
Employees
9,900
Market Cap
12.44B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.72B | 276.00M | 6.22% |
| Dec 31, 2024 | 4.44B | 22.00M | 0.50% |
| Dec 31, 2023 | 4.42B | 6.00M | 0.14% |
| Dec 31, 2022 | 4.41B | -353.00M | -7.41% |
| Dec 31, 2021 | 4.76B | 1.49B | 45.64% |
| Dec 31, 2020 | 3.27B | 200.00M | 6.51% |
| Dec 31, 2019 | 3.07B | 4.20M | 0.14% |
| Dec 31, 2018 | 3.07B | 177.80M | 6.15% |
| Dec 31, 2017 | 2.89B | -24.50M | -0.84% |
| Dec 31, 2016 | 2.91B | 4.40M | 0.15% |
| Dec 31, 2015 | 2.91B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viatris | 14.56B |
| Zoetis | 9.53B |
| Dr. Reddy's Laboratories | 3.50B |
| United Therapeutics | 3.17B |
| Neurocrine Biosciences | 3.10B |
| Amneal Pharmaceuticals | 3.05B |
| Hims & Hers Health | 2.37B |
| Alkermes | 1.56B |
ELAN News
- 3 days ago - Elanco price target raised to $26 from $23 at Morgan Stanley - TheFly
- 3 days ago - Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets) - PRNewsWire
- 17 days ago - Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement - PRNewsWire
- 5 weeks ago - Elanco price target raised to $32 from $31 at TD Cowen - TheFly
- 5 weeks ago - Elanco to launch Elanco Ventures for animal health innovation - TheFly
- 5 weeks ago - Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health - PRNewsWire
- 5 weeks ago - Elanco announces USDA approval of TruCan Ultra Lyme-L4 - TheFly
- 5 weeks ago - Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs - PRNewsWire